After a brief news lull around medtech regulatory system changes for the UK, the government and Medicines and Healthcare products Regulatory Agency (MHRA) issued several updates on new structures and access to medtech and healthtech in late May.
Among them was the government’s response to the chief scientific advisor’s (CSA) report on the pro-innovation regulation of emerging life science technologies, with a strong focus on advancing medtech.
Key Takeaways
-
MHRA asked to work alongside approved bodies on UKCA approvals
-
Pilot launch of IDAP set for later in 2023...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?